Analysts See $-0.20 EPS for SCYNEXIS, Inc. (SCYX)

October 13, 2018 - By Ash

Investors sentiment decreased to 0.93 in Q2 2018. Its down 1.67, from 2.6 in 2018Q1. It dived, as 8 investors sold SCYNEXIS, Inc. shares while 6 reduced holdings. 6 funds opened positions while 7 raised stakes. 18.42 million shares or 0.71% more from 18.29 million shares in 2018Q1 were reported.
Morgan Stanley accumulated 300 shares. Federated Inc Pa has 0.03% invested in SCYNEXIS, Inc. (NASDAQ:SCYX) for 6.87M shares. Creative Planning holds 48,476 shares. 266,803 are owned by Jpmorgan Chase And Com. 40,000 were accumulated by Spark Investment Mgmt Lc. Dimensional Fund Advisors Lp invested in 0% or 245,580 shares. Blackrock holds 180,751 shares or 0% of its portfolio. 470,130 were reported by Geode Capital Management Ltd Company. 116,079 were accumulated by Northern Corp. Caxton, New Jersey-based fund reported 2.96 million shares. Rock Springs Cap Management Ltd Partnership accumulated 820,000 shares. Opus Point Partners Ltd reported 0.12% stake. Moore Cap Management Lp holds 0.01% or 225,000 shares in its portfolio. Broadfin Cap Limited Liability has invested 0.49% of its portfolio in SCYNEXIS, Inc. (NASDAQ:SCYX). Moreover, Bridgeway Capital Incorporated has 0% invested in SCYNEXIS, Inc. (NASDAQ:SCYX).

Since August 23, 2018, it had 2 insider buys, and 0 sales for $41,140 activity. Shares for $8,890 were bought by Angulo Gonzalez David on Thursday, September 6.

Analysts expect SCYNEXIS, Inc. (NASDAQ:SCYX) to report $-0.20 EPS on November, 6.They anticipate $0.07 EPS change or 25.93 % from last quarter’s $-0.27 EPS. After having $-0.23 EPS previously, SCYNEXIS, Inc.’s analysts see -13.04 % EPS growth. The stock decreased 1.65% or $0.02 during the last trading session, reaching $1.19. About 129,793 shares traded. SCYNEXIS, Inc. (NASDAQ:SCYX) has declined 41.01% since October 14, 2017 and is downtrending. It has underperformed by 56.63% the S&P500.

SCYNEXIS, Inc. (NASDAQ:SCYX) Ratings Coverage

Among 4 analysts covering SCYNEXIS (NASDAQ:SCYX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SCYNEXIS had 4 analyst reports since May 7, 2018 according to SRatingsIntel. The rating was reinitiated by Canaccord Genuity with “Buy” on Friday, June 29. The stock of SCYNEXIS, Inc. (NASDAQ:SCYX) earned “Buy” rating by H.C. Wainwright on Monday, May 7.

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. The company has market cap of $55.95 million. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. It currently has negative earnings. The firm also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis.

SCYNEXIS, Inc. (NASDAQ:SCYX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News